Orphazyme Stock Analysis

ORPH -  USA Stock  

USD 16.78  0.57  3.52%

The current price rise of Orphazyme AS ADR may encourage stockholders to take a closer look at the company as it is trading at a share price of 16.78 on 61,507,971 in trading volume. The company directors and management may have good odds in positioning the company resources to exploit market volatility in July. The stock standard deviation of daily returns for 90 days investing horizon is currently 13.99. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Orphazyme partners.
Please check Your Equity Center.

Search Stock Analysis 

The Orphazyme stock analysis report makes it easy to digest most publicly released information about Orphazyme and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Orphazyme stock analysis module also helps to analyze the Orphazyme price relationship with some important fundamental indicators such as market cap and management efficiency.

Orphazyme Stock Analysis Notes

The company had not issued any dividends in recent years. Orphazyme AS, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company was founded in 2009 and is headquartered in Copenhagen, Denmark. Orphazyme operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 114 people. To find out more about Orphazyme AS ADR contact the company at 45 39 17 82 72 or learn more at http://www.orphazyme.com.

Orphazyme AS ADR Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Orphazyme's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Orphazyme AS ADR or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Orphazyme AS ADR is way too risky over 90 days horizon
Orphazyme AS ADR appears to be risky and price may revert if volatility continues
Orphazyme AS ADR has high likelihood to experience some financial distress in the next 2 years
Latest headline from www.nasdaq.com: Todays Market Gold Versus Gold Miners - Nasdaq

Orphazyme SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Orphazyme prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Orphazyme investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Orphazyme AS ADR specific information freely available to individual and institutional investors to make a timely investment decision.

Orphazyme Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 314.52 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Orphazyme's market, we take the total number of its shares issued and multiply it by Orphazyme's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (54.49) % which means that it has lost $54.49 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (116.29) %, meaning that it created substantial loss on money invested by shareholders. Orphazyme management efficiency ratios could be used to measure how well orphazyme as adr manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 17th of June 2021, Orphazyme holds the Risk Adjusted Performance of 0.0212, semi deviation of 9.49, and Coefficient Of Variation of 5321.01. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Orphazyme, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Orphazyme AS ADR, which can be compared to its competitors. Please check Orphazyme AS ADR variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Orphazyme AS ADR is priced some-what accurately, providing market reflects its current price of 16.78 per share. Given that Orphazyme has jensen alpha of 0.2902, we recommend you to check out Orphazyme AS ADR's recent market performance to make sure the company can sustain itself at a future point.

Orphazyme AS ADR Price Movement Analysis

The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Exponential Moving Average is calculated by weighting recent values of Orphazyme AS ADR more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Orphazyme Predictive Daily Indicators

Orphazyme intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Orphazyme stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Orphazyme Forecast Models

Orphazyme time-series forecasting models is one of many Orphazyme's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Orphazyme's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Orphazyme Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Orphazyme stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Orphazyme shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Orphazyme. By using and applying Orphazyme Stock analysis, traders can create a robust methodology for identifying Orphazyme entry and exit points for their positions.
Orphazyme AS, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company was founded in 2009 and is headquartered in Copenhagen, Denmark. Orphazyme operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 114 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Orphazyme to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Idea Optimizer Now


Idea Optimizer

Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
All  Next Launch Module
Please check Your Equity Center. Note that the Orphazyme AS ADR information on this page should be used as a complementary analysis to other Orphazyme's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Probability Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Complementary Tools for Orphazyme Stock analysis

When running Orphazyme AS ADR stock analysis, check to measure Orphazyme's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orphazyme is operating at the current time. Most of Orphazyme's stock examination focuses on studying past and present price action to predict the probability of Orphazyme's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Orphazyme's price. Additionally, you may evaluate how the addition of Orphazyme to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
ETF Directory
Find actively-traded Exchange Traded Funds (ETF) from around the world
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
The market value of Orphazyme AS ADR is measured differently than its book value, which is the value of Orphazyme that is recorded on the company's balance sheet. Investors also form their own opinion of Orphazyme stock's value that differs from its market value or its book value, called intrinsic value, which is Orphazyme's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orphazyme's market value can be influenced by many factors that don't directly affect Orphazyme AS ADR underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orphazyme's stock value and its price as these two are different measures arrived at by different means. Investors typically determine Orphazyme value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orphazyme's stock price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.